Successful in withdrawal from corticosteroid therapy by co-administration of PSL with Sairei-tou in a case of middle-age woman with PBC-AIH overlap syndrome

DOI Web Site Web Site 17 References

Bibliographic Information

Other Title
  • 中年女性のPBC-AIH overlap syndromeに対して柴苓湯を併用し，ステロイドホルモン剤から離脱できた1例
  • 症例報告 中年女性のPBC-AIH overlap syndromeに対して柴苓湯を併用し,ステロイドホルモン剤から離脱できた1例
  • ショウレイ ホウコク チュウネン ジョセイ ノ PBC-AIH overlap syndrome ニ タイシテ サイレイトウ オ ヘイヨウ シ,ステロイドホルモンザイ カラ リダツ デキタ 1レイ

Search this article

Abstract

The patient was a 51-year-old female diagnosed with PBC-AIH overlap syndrome (OLS) at our hospital. Ursodeoxycholic acid (UDCA) 900 mg and predonisolone (PSL) 2.5 mg had been orally administered at our outpatient department to maintain the level of transaminase within the normal ranges since 2009. Since she complained of very serious insomnia during the oral administration of PSL, the PSL treatment was discontinued two years after initiation. Her insomnia improved after discontinuance of PSL, however the hepatic enzyme levels had gradually increased (AST 55 IU/l and ALT 75 IU/l). Then, to reduce insomnia and other side effect of corticosteroid, PSL 20 mg and Sairei-tou 9.0 g were administrated. Since in the four weeks from initiation of co-administration of PSL with Sairei-tou, the transaminase levels were normalized quickly, the dose of PSL was decreased. Although oral administration of PSL was discontinued after 12 weeks from the start of co-administration of PLS with Sairei-tou, the improved transaminase levels have been maintained without aggravation for about 1 year. In this study we report the case of a middle-aged female with OLS who could stop taking PSL by co-administration with Sairei-tou.

Journal

  • Kanzo

    Kanzo 54 (10), 705-712, 2013

    The Japan Society of Hepatology

References(17)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top